By City News Service
Apr 1, 2021
LOS ANGELES (CNS) - A single dose of the Pfizer-BioNTech vaccine for people who have already had COVID-19 generates an immunologic response similar to that in people who receive the two-dose recommended sequence, according to a study released today by researchers at Cedars-Sinai.
The study suggests that the second dose may not be needed for people who have successfully recovered from a prior coronavirus infection, according to Dr. Susan Cheng, an associate professor of cardiology and director of Public Health Research at the Smidt Heart Institute at Cedars-Sinai.
“Our findings extend those from smaller studies reported elsewhere and support a potential strategy of providing a single dose of vaccine to persons with a confirmed prior history of coronavirus infection, along with two doses for people not previously infected, Cheng said. “This approach could maximize the reach of a limited vaccine supply, allowing potentially millions more people
More than 11,000 cases of a troubling variant reported in the US These states have the highest numbers
ktvz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ktvz.com Daily Mail and Mail on Sunday newspapers.
Cedars-Sinai: Community Main Source of COVID Exposure for Health Workers
iheart.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iheart.com Daily Mail and Mail on Sunday newspapers.
Clinical Trials Are Moving Out of the Lab and Into Peopleâs Homes
After the pandemic forced thousands of trials to shut down, researchers found clever ways to conduct human studies remotely â while reaching more people, quickly and cheaply.
Dr. Namandje Bumpus, a pharmacologist at Johns Hopkins University, is leading an investigation that has been on hold because of the pandemic.Credit.Michael A. McCoy for The New York Times
By Emily Anthes
Feb. 18, 2021
When the pandemic hit last year, clinical trials took a hit. Universities closed, and hospitals turned their attention to battling the new disease. Many studies that required repeated, in-person visits with volunteers were delayed or scrapped.